🔗 Share this article

The recently developed medications for gonorrhoea in decades are being viewed as a "major milestone" in the battle against increasingly resistant strains of the bacteria, according to health experts.

A Worldwide Challenge

The sexually transmitted infection are escalating globally, with figures suggesting over 82 million infections annually. Particularly high rates are observed in Africa and nations within the World Health Organization's Western Pacific region, which includes China and Mongolia to New Zealand. Across England, cases have reached a record high, while figures across Europe in 2023 were triple the level compared to the rates from 2014.

“The clearance of new treatments for gonorrhoea is an important and timely advancement in the reality of growing infection rates, increasing antimicrobial resistance and the highly restricted therapeutic options at this time.”

Medical experts are particularly alarmed about the rise in treatment-resistant strains. The World Health Organization has listed it as a "high-priority threat". Ongoing monitoring revealed that resistance to standard treatments like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

A Pair of Novel Treatment Options Gain Clearance

Zoliflodacin, marketed under the name a brand name, was approved by the American regulatory agency in mid-December for combating gonorrhoea. This STI can lead to significant complications, including infertility. Researchers anticipate that focused deployment of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, developed by the pharmaceutical company GlaxoSmithKline, gained clearance in concurrent days. This drug, which is employed against urinary tract infections, was proven in research to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Partnership

This new treatment emerged from a innovative non-profit model for medication research. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the drug firm its industry partner to develop it.

“This approval signifies a significant shift in the treatment of superbug gonorrhoea, which up to this point has been staying ahead of our drug pipeline.”

Clinical Trial Data and Global Access

According to results detailed in a major medical journal, zoliflodacin cured over nine in ten of uncomplicated infections. This puts it on an similar efficacy with the current standard treatment, which combines two antibiotics. The trial included over 900 volunteers from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, GARDP has the rights to make available and distribute the drug in numerous low-income and middle-income countries.

Clinicians directly involved have voiced optimism. The availability of a single-dose, oral treatment such as this is seen as a "revolutionary step" for managing the epidemic. This is deemed vital to reduce the burden of the infection for individuals and to prevent the spread of extremely resistant gonorrhoea globally.